Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common shares
-
Shares outstanding
-
250,425,788
-
Total 13F shares
-
64,980,785
-
Share change
-
-7,799,480
-
Total reported value
-
$102,682,821
-
Put/Call ratio
-
6.7%
-
Price per share
-
$1.58
-
Number of holders
-
84
-
Value change
-
-$12,116,491
-
Number of buys
-
30
-
Number of sells
-
51
Institutional Holders of Lineage Cell Therapeutics, Inc. - Common shares (LCTX) as of Q2 2022
As of 30 Jun 2022,
Lineage Cell Therapeutics, Inc. - Common shares (LCTX) was held by
84 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
64,980,785 shares.
The largest 10 holders included
BROADWOOD CAPITAL INC, VANGUARD GROUP INC, Defender Capital, LLC., BlackRock Inc., Laurion Capital Management LP, RAFFLES ASSOCIATES LP, Prescott General Partners LLC, JPMORGAN CHASE & CO, GEODE CAPITAL MANAGEMENT, LLC, and MILLENNIUM MANAGEMENT LLC.
This page lists
84
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.